tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2015 Jun 22:1-10. [Epub ahead of print]
[h=1]The avian influenza vaccine Emerflu. Why did it fail?[/h] Young BE[SUP]1[/SUP], Sadarangani SP, Leo YS.
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerflu is an inactivated, split-virion pandemic preparedness vaccine, containing 30 μg of hemagglutinin (HA) and 600 μg of aluminum hydroxide adjuvant. It is administered in two doses, 3 weeks apart. Only moderate immunogenicity was evident from clinical studies with the vaccine in adults, and HA antibody responses were below the criteria established by the EMA and US FDA for licensure. With the exception of Australia, the vaccine remains unlicensed. Further clinical development appears to have been suspended, and newer adjuvants such as MF59 and AS03 have since demonstrated safety and superior immunogenicity with lower HA doses. Emerflu is symbolic of the failure of aluminum salts as an adjuvant for influenza vaccines. Reasons for this failure are unclear, and may reflect problems with the adjuvant-antigen complex or interference in the immune response by heterosubtypic immunity.
[h=4]KEYWORDS:[/h] Emerflu; H5N1; adjuvant; alum; avian; influenza; split; vaccine; virion
PMID: 26098721 [PubMed - as supplied by publisher]
[h=1]The avian influenza vaccine Emerflu. Why did it fail?[/h] Young BE[SUP]1[/SUP], Sadarangani SP, Leo YS.
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerflu is an inactivated, split-virion pandemic preparedness vaccine, containing 30 μg of hemagglutinin (HA) and 600 μg of aluminum hydroxide adjuvant. It is administered in two doses, 3 weeks apart. Only moderate immunogenicity was evident from clinical studies with the vaccine in adults, and HA antibody responses were below the criteria established by the EMA and US FDA for licensure. With the exception of Australia, the vaccine remains unlicensed. Further clinical development appears to have been suspended, and newer adjuvants such as MF59 and AS03 have since demonstrated safety and superior immunogenicity with lower HA doses. Emerflu is symbolic of the failure of aluminum salts as an adjuvant for influenza vaccines. Reasons for this failure are unclear, and may reflect problems with the adjuvant-antigen complex or interference in the immune response by heterosubtypic immunity.
[h=4]KEYWORDS:[/h] Emerflu; H5N1; adjuvant; alum; avian; influenza; split; vaccine; virion
PMID: 26098721 [PubMed - as supplied by publisher]